

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF KANSAS**

**IN RE: EpiPen (Epinephrine
Injection, USP) Marketing,
Sales Practices and Antitrust
Litigation**

MDL No: 2785

Case No. 17-md-2785-DDC-TJJ

**(This Document Applies to
Consumer Class Cases)**

**ORDER ADOPTING SCHEDULING ORDER NO. 16 (SECOND AMENDED
TRIAL ORDER)**

This Order adopts Scheduling Order No. 16. And, it amends the Amended Trial Order (Doc. 2415) issued on August 24, 2021.

At the Final Pretrial Conference on January 10, 2022, the court granted the Mylan Defendants' request to continue the trial from its current setting on January 24, 2022. The court agreed that a four-week continuance of the trial is warranted in light of the current public health conditions and the present surge in COVID-19 infections caused by the Omicron variant. Thus, the court reschedules the trial to begin on **Tuesday, February 22, 2022**. Also, the court enters the following revised schedule to reset other pretrial deadlines consistent with the rescheduled trial setting on February 22, 2022. The following deadlines supersede any deadlines previously established by the Amended Trial Order (Doc. 2415), or any other others.

<u>Event</u>	<u>Deadline</u>
Joint Jury Instructions with Alternative Instructions	Wednesday, February 2, 2022

Submit Exhibits to Court (Scheduling Order No. 14 (Doc. 2346))	Friday, February 11, 2022
Submit Agreed Voir Dire Questions for the court to ask at trial, plus any not agreed to	Friday, February 11, 2022
Jury Questionnaire Responses Available to Liaison Counsel	Friday, February 11, 2022
Trial	Tuesday, February 22, 2022, at 9:00 am

IT IS SO ORDERED.

Dated this 12th day of January, 2022, at Kansas City, Kansas.

s/ Daniel D. Crabtree
Daniel D. Crabtree
United States District Judge